Document is current

Article History

Received: 25 April 2025

Accepted: 30 June 2025

First Online: 22 July 2025

Declarations

:

: MH reports no conflicts of interest.TM receives speaker’s honoraria from Jazz Pharma, UCB, and Angelini Pharma.KAK received speaker’s honoraria from Biocodex, Desitin, Eisai, Jazz Pharmaceuticals, and UCB Pharma.SK received speaker’s honoraria from Bial, Destin Arzneimittel, Eisai, Jazz Pharma, Merck Serono, and UCB.FvP received personal fees and grants from Angelini Pharma, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, UCB Pharma, Nutricia Milupa GmbH, Neuraxpharm, and Bial.GK received speaker’s honoraria from Angelini Pharma, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, Takeda, UCB Pharma, Neuraxpharm, Stada Arzneimittel, Precisis GmbH, and Alexion Pharmaceuticals.II received personal fees from Angelini Pharma, Jazz Pharmaceuticals, and Precisis.FR received personal fees and grants from Angelini Pharma, Desitin Arzneimittel, Dr. Schär Deutschland GmbH, Eisai Pharma, Jazz Pharma, Nutricia Milupa GmbH, Stoke Therapeutics, Takeda, UCB Pharma and Vitaflo Deutschland GmbH. Research support from the European Union (EU-FP7), German Research Foundation (DFG), Federal State of Hesse, Germany, Detlev Wrobel Fonds for Epilepsy Research, Reiss-Stiftung, Dr. Senckenbergische-Stiftung, Kassel-Stiftung, Ernst Max von Grunelius-Stiftung, Chaja-Stiftung.SSB received personal fees and grants from Angelini Pharma, Biocodex, Biomarin, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, Takeda, and UCB Pharma.AS received personal fees and grants from Angelini Pharma, Biocodex, Desitin Arzneimittel, Eisai, Jazz Pharmaceuticals, Longboard, Neuraxpharm, Stoke Therapeutics, Takeda, UCB Pharma, and UNEEG Medical.

: Ethics committee approval was obtained.

: Waived due to the retrospective nature of the study.

: Not applicable.